1. A method of providing access to an asset via a computing environment security agent, the method comprising:
authenticating a user for computing environment access;
receiving a request from the authenticated user to access an asset; and
determining whether the authenticated user is authorized to access the asset, and if so, determining whether to transform the asset responsive to the request to access the asset by the authenticated user.
2. The method of claim 1, further comprising automatically defining a transformation rule for the requested asset when the determining determines that transformation is to occur.
3. The method of claim 2, further comprising allowing authenticated user access to a transformed asset, the transformed asset being identified by the transformation rule and access thereto being automatically allowed responsive to the request by the authenticated user for access to the asset.
4. The method of claim 2, further comprising transforming the requested asset transparent to the authenticated user.
5. The method of claim 1, further comprising automatically defining at least one transformation rule for the requested asset when the determining determines that transformation is to occur, saving the at least one transform rule in a transformation list, and allowing the authenticated user to access the transformation list to select a transformation rule therefrom.
6. The method of claim 5, wherein the allowing access to the transformation list is responsive to a request therefor received from the authenticated user, the request for the transformation list being received subsequent to sending an access rejection to the authenticated user responsive to the authenticated user’s request to access the asset.
7. The method of claim 6, further comprising allowing the authenticated user access to a transformed asset defined by the user selected transformation rule from the transformation list.
8. The method of claim 1, further comprising allowing the authenticated user access to the requested asset when authorized and when no transformation of the asset is to occur.
9. A system of providing access to an asset of a computing environment, the system comprising:
a computing environment security agent, the computing environment security agent comprising:
means for authenticating a user for computing environment access;
means for receiving a request from the authenticated user to access an asset; and
means for determining whether the authenticated user is authorized to access the asset, and if so, for determining whether to transform the asset responsive to the request to access the asset by the authenticated user.
10. The system of claim 9, further comprising means for automatically defining a transformation rule for the requested asset when the means for determining determines that transformation is to occur.
11. The system of claim 10, further comprising means for allowing authenticated user access to a transformed asset, the transformed asset being identified by the transformation rule and access thereto being automatically allowed responsive to the request by the authenticated user for access to the asset.
12. The system of claim 10, further comprising means for transforming the requested asset transparent to the authenticated user.
13. The system of claim 9, further comprising means for automatically defining at least one transformation rule for the requested asset when the means for determining determines that transformation is to occur, means for saving the at least one transform rule in a transformation list, and means for allowing the authenticated user to access the transformation list to select a transformation rule therefrom.
14. The system of claim 13, wherein the means for allowing access to the transformation list is responsive to a request therefor received from the authenticated user, the request for the transformation list being received subsequent to sending an access rejection to the authenticated user responsive to the authenticated user’s request to access the asset.
15. The system of claim 14, further comprising means for allowing the authenticated user access to a transformed asset defined by the user selected transformation rule from the transformation list.
16. The system of claim 9, further comprising means for allowing the authenticated user access to the requested asset when authorized and when no transformation of the asset is to occur.
17. A security system for a computing environment comprising:
a security agent for controlling access to an asset of the computing environment, the security agent:
authenticating a user for computing environment access;
receiving a request from the authenticated user to access an asset; and
determining whether the authenticated user is authorized to access the asset, and if so, determining whether to transform the asset responsive to the request to access the asset by the authenticated user.
18. At least one program storage device readable by a machine embodying at least one program of instructions executable by the machine to perform a method of providing access to an asset via a computing environment security agent, the method comprising:
authenticating a user for computing environment access;
receiving a request from the authenticated user to access an asset; and
determining whether the authenticated user is authorized to access the asset, and if so, determining whether to transform the asset responsive to the request to access the asset by the authenticated user.
19. The at least one program storage device of claim 18, further comprising automatically defining a transformation rule for the requested asset when the determining determines that transformation is to occur.
20. The at least one program storage device of claim 19, further comprising allowing authenticated user access to a transformed asset, the transformed asset being identified by the transformation rule and access thereto being automatically allowed responsive to the request by the authenticated user for access to the asset.
21. The at least one program storage device of claim 19, further comprising transforming the requested asset transparent to the authenticated user.
22. The at least one program storage device of claim 18, further comprising automatically defining at least one transformation rule for the requested asset when the determining determines that transformation is to occur, saving the at least one transform rule in a transformation list, and allowing the authenticated user to access the transformation list to select a transformation rule therefrom.
23. The at least one program storage device of claim 22, wherein the allowing access to the transformation list is responsive to a request therefor received from the authenticated user, the request for the transformation list being received subsequent to sending an access rejection to the authenticated user responsive to the authenticated user’s request to access the asset.
24. The at least one program storage device of claim 23, further comprising allowing the authenticated user access to a transformed asset defined by the user selected transformation rule from the transformation list.
25. The at least one program storage device of claim 18, further comprising allowing the authenticated user access to the requested asset when authorized and when no transformation of the asset is to occur.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of diagnosing a cancer that overexpresses YY1 protein andor augments YY1 transcriptional activity, the method comprising the steps of:
(a) contacting a tissue sample with an antibody that specifically binds to YY1 protein; and
(b) determining whether or not YY1 protein is overexpressed in the sample; thereby diagnosing the cancer that overexpresses YY1.
2. The method of claim 1, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, breast cancer, colon cancer, lung cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
3. The method of claim 1, wherein the tissue sample is a needle biopsy, a surgical biopsy or a bone marrow biopsy.
4. The method of claim 3, wherein the tissue sample is at least one of fixed or embedded in paraffin.
5. The method of claim 1, wherein the antibody is a monoclonal antibody.
6. A method of diagnosing a cancer that overexpresses YY1, the method comprising the steps of:
(a) contacting a tissue sample with a primer set of a first oligonucleotide and a second oligonucleotide that each specifically hybridize to YY1 nucleic acid;
(b) amplifying YY1 nucleic acid in the sample; and
(c) determining whether or not YY1 nucleic acid is overexpressed in the sample; thereby diagnosing the cancer that overexpresses YY1.
7. The method of claim 6, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, breast cancer, colon cancer, lung cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
8. The method of claim 4, wherein the tissue sample is microlasar microdissected cells from a needle biopsy, a surgical biopsy, or a bone marrow biopsy.
9. The method of claim 4, wherein the first oligonucleotide comprises SEQ ID NO:1 and the second oligonucleotide comprises SEQ ID NO:2.
10. A method of providing a prognosis for a cancer that overexpresses YY1 protein or biological activity, the method comprising the steps of:
(a) contacting a tissue sample with an antibody that specifically binds to YY1 protein; and
(b) determining whether or not YY1 protein is overexpressed in the sample; thereby providing a prognosis for the cancer that overexpresses YY1.
11. The method of claim 10, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, breast cancer, colon cancer, lung cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
12. The method of claim 10, wherein the tissue sample is a needle biopsy, a surgical biopsy or a bone marrow biopsy.
13. The method of claim 10, wherein the antibody is a monoclonal antibody.
14. The method of claim 10, wherein the tissue sample is a metastatic cancer tissue sample.
15. The method of claim 10, wherein the tissue sample is from prostate, ovary, bone, lymph node, liver, or kidney.
16. A method of providing a prognosis for a cancer that overexpresses YY1, the method comprising the steps of:
(a) contacting a tissue sample with a primer set of a first oligonucleotide and a second oligonucleotide that each specifically hybridize to YY1 nucleic acid;
(b) amplifying YY1 nucleic acid in the sample; and
(c) determining whether or not YY1 nucleic acid is overexpressed in the sample; thereby providing a prognosis for the cancer that overexpresses YY1.
17. The method of claim 16, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, lung cancer, breast cancer, colon cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
18. The method of claim 16, wherein the first oligonucleotide comprises SEQ ID NO:1 and the second oligonucleotide comprises SEQ ID NO:2.
19. The method of claim 16, wherein the tissue sample is a needle biopsy, a surgical biopsy or a bone marrow biopsy.
20. The method of claim 16, wherein the tissue sample is a metastatic cancer tissue sample.
21. The method of claim 16, wherein the tissue sample is from prostate, ovary, bone, lymph node, liver, or kidney.
22. An isolated primer set, the primer set comprising a first oligonucleotide and a second oligonucleotide, the oligonucleotides comprising a nucleotide sequence of 50 nucleotides or less; wherein the first oligonucleotide comprises SEQ ID NO:1 and the second oligonucleotide comprises SEQ ID NO:2.
23. A method of localizing a cancer that overexpresses YY1 in vivo, the method comprising the step of imaging in a subject a cell overexpressing YY1 polypeptide, thereby localizing cancer in vivo.
24. The method of claim 23, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, breast cancer, lung cancer, colon cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
25. A method of identifying a compound that inhibits a cancer that overexpresses YY1, the method comprising the steps of:
(a) contacting a cell expressing YY1 polypeptide with a compound; and
(b) determining the effect of the compound on the YY1 polypeptide; thereby identifying a compound that inhibits the cancer that overexpresses YY1.
26. The method of claim 25, wherein the compound inhibits the binding of YY1 to a DNA sequence.
27. The method of claim 25, wherein the cell comprises a promoter sequence bound by YY1 operably linked to a reporter nucleic acid sequence.
28. The method of claim 25, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, lung cancer, breast cancer, colon cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
29. A method of identifying a compound that inhibits a therapy resistant cancer, the method comprising the steps of:
(a) contacting a cell expressing YY1 polypeptide with a compound; and
(b) determining the effect of the compound on the YY1 polypeptide; thereby identifying a compound that inhibits the therapy resistant cancer.
30. The method of claim 29, wherein the compound inhibits the binding of YY1 to a DNA sequence.
31. The method of claim 29, wherein the compound sensitizes the cell to apoptosis induced by cell signaling through a death receptor.
32. The method of claim 29, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, lung cancer, breast cancer, colon cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
33. A method of treating or inhibiting a cancer that overexpresses YY1 in a subject comprising administering to the subject a therapeutically effective amount of one or more YY1 inhibitors.
34. The method of claim 33, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, lung cancer, breast cancer, colon cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
35. The method of claim 33, wherein the YY1 inhibitor is an NO donor.
36. The method of claim 35, wherein the NO donor is selected from the group consisting of L-arginine, amyl nitrite, isoamyl nitrite, nitroglycerin, isosorbide dinitrate, isosorbide-2-mononitrate, isosorbide-5-mononitrate, erythrityl tetranitrate, pentaerythritol tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, N-hydroxyl-L-arginine, S,S-dinitrosodthiol, ethylene glycol dinitrate, isopropyl nitrate, glyceryl-1-mononitrate, glyceryl-1,2-dinitrate, glyceryl-1,3-dinitrate, glyceryl trinitrate, butane-1,2,4-triol trinitrate, N,O-diacetyl-N-hydroxy-4-chlorobenzenesulfonamide, NG-hydroxy-L-arginine, hydroxyguanidine sulfate, (\xb1)-S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, (\xb1)-(E)-ethyl-2-(E)-hydroxyimino-5-nitro-3-hexeneamide (FK409), (\xb1)-N-(E)-4-ethyl-3-(Z)-hydroxyimino-5-nitro-3-hexen-1-yl-3-pyridinecarboxamide (FR144420), 4-hydroxymethyl-3-furoxancarboxamide, (Z)-1-2-(2-Aminoethyl)-N-(2-ammonioethyl)aminodiazen-1-ium-1,2-diolate; NOC-18; 3,3-bis(aminoethyl)-1-hydroxy-2-oxo-*1-triazene (DETANONOate), NO gas, and mixtures thereof.
37. The method of claim 33, wherein the YY1 inhibitor is an inhibitory RNA.
38. The method of claim 33, wherein the YY1 inhibitor is an antimitotic drug.
39. The method of claim 38, wherein the antimitotic drug is selected from the group consisting of vinca alkaloids and taxanes.
40. A method of treating or inhibiting a therapy resistant cancer in a subject comprising administering to the subject a therapeutically effective amount of one or more YY1 inhibitors.
41. The method of claim 40, wherein the one or more YY1 inhibitors are administered concurrently with another cancer therapy.
42. The method of claim 40, wherein the cancer that overexpresses YY1 is selected from the group consisting of prostate cancer, ovarian cancer, renal cancer, lung cancer, breast cancer, colon cancer, leukemia, non-Hodgkin’s lymphoma, multiple myeloma and hepatocarcinoma.
43. The method of claim 40, wherein the YY1 inhibitor is an NO donor.
44. The method of claim 43, wherein the NO donor is selected from the group consisting of L-arginine, amyl nitrite, iso amyl nitrite, nitroglycerin, isosorbide dinitrate, isosorbide-2-mononitrate, isosorbide-5-mononitrate, erythrityl tetranitrate, pentaerythritol tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, N-hydroxyl-L-arginine, S,S-dinitrosodthiol, ethylene glycol dinitrate, isopropyl nitrate, glyceryl-1-mononitrate, glyceryl-1,2-dinitrate, glyceryl-1,3-dinitrate, glyceryl trinitrate, butane-1,2,4-triol trinitrate, N,O-diacetyl-N-hydroxy-4-chlorobenzenesulfonamide, NG-hydroxy-L-arginine, hydroxyguanidine sulfate, (\xb1)-S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, (\xb1)-(E)-ethyl-2-(E)-hydroxyimino-5-nitro-3-hexeneamide (FK409), (\xb1)-N-(E)-4-ethyl-3-(Z)-hydroxyimino-5-nitro-3-hexen-1-yl-3-pyridinecarboxamide (FR144420), 4-hydroxymethyl-3-furoxancarboxamide, (Z)-1-2-(2-Aminoethyl)-N-(2-ammonioethyl)aminodiazen-1-ium-1,2-diolate; NOC-18; 3,3-bis(aminoethyl)-1-hydroxy-2-oxo-*1-triazene (DETANONOate), NO gas, and mixtures thereof.
45. The method of claim 40, wherein the YY1 inhibitor is an inhibitory RNA.
46. The method of claim 40, wherein the YY1 inhibitor is an antimitotic drug.
47. The method of claim 46, wherein the antimitotic drug is selected from the group consisting of vinca alkaloids and taxanes.